The development of the NanoEcho imaging device completed and ready for clinical studies
Today, the formal verification has been successfully completed without any remarks, which is the final step in product development. The system now meets the requirements of customers and authorities for medical devices. This means that NanoEcho’s commercial imaging system is fully developed and ready to be used on patients in clinical studies. “This is a […]
Affärsvärlden highlights NanoEcho in an article
NanoEcho is featured in an article published by Affärsvärlden! In the interview with Linda Persson, you can read about NanoEcho and the ongoing emission. ‘Our technology has several advantages. We address an issue with inadequate diagnostics, which means less suffering for the patient and lower costs for healthcare,’ says Linda Persson. Read the full article […]
Watch our live company presentation with NanoEcho’s CEO
Did you miss our live company presentation with NanoEcho’s CEO, Linda Persson, yesterday? No worries, you can watch it afterwards. The presentation is now also subtitled. NanoEcho is currently conducting a new share issue to enter the clinical phase with our patented diagnostic method. The goal is to improve healthcare by providing patients with rectal […]
NanoEcho invites you to a live company presentation
On Monday, June 10 at 5:00 PM, NanoEcho invites you to a live company presentation in light of the ongoing share issue. The presentation will be conducted by our CEO, Linda Persson. This is an excellent opportunity to get to know NanoEcho and our efforts to provide future healthcare with more precise, simple, and cost-effective […]
Finwire Media publishes presentation of NanoEcho ahead of IPO
Ahead of the upcoming stock exchange listing, Finwire Media has published a presentation where our CEO, Linda Persson, discusses NanoEcho’s technology with the aim of improving the diagnosis of rectal cancer and creating significant health-economic benefits for society. Linda also shares her insights on the company’s strategy to get the system approved and implemented as […]
Interview with CEO, Linda Persson, in Privata Affärer
𝐃𝐨 𝐲𝐨𝐮 𝐰𝐚𝐧𝐭 𝐭𝐨 𝐤𝐧𝐨𝐰 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐍𝐚𝐧𝐨𝐄𝐜𝐡𝐨’𝐬 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐦𝐞𝐭𝐡𝐨𝐝 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐨𝐧𝐠𝐨𝐢𝐧𝐠 𝐬𝐡𝐚𝐫𝐞 𝐢𝐬𝐬𝐮𝐞? Don’t miss the interview with our CEO, Linda Persson, in Privata Affärer. NanoEcho is currently conducting a new share issue to enter the clinical phase with our patented diagnostic method, which aims to improve healthcare by providing patients with […]
An inspiring Saturday with a goal-oriented team!
Today NanoEcho run the Lundaloppet together through a flourishing Lund – and what fantastic performances! Combining health with team building is a powerful union for promoting collaboration and well-being. Prioritising health not only provides physical benefits but also increases energy levels and improves focus and performance at work. An inspiring Saturday with a goal-oriented team!
CEO Linda Persson summarises the first quarter of 2024
Don’t miss when CEO Linda Persson summarises the first quarter of 2024 in conjunction with the published quarterly report. We can confirm that NanoEcho once again leaves behind an eventful quarter, during which we have successfully reached several important milestones. “During this quarter, we have achieved significant milestones in our efforts to improve rectal cancer […]
A day at the endoscopy unit at SUS
Ulrika Axelsson, Clinical Director at NanoEcho, swapped a day in the office for a day at the endoscopy unit at Skåne University Hospital (SUS) in Malmö, to follow Professor Henrik Thorlacius, Associate Professor Carl-Fredrik Rönnow, and their colleagues. Several local procedures were performed during the day to remove rectal tumors, known as ESD (Endoscopic Submucosal […]
Significant milestone achieved – CEO Linda Persson tells about the business agreement with SPL Medical
Listen as our CEO, Linda Persson, tells about the significant milestone achieved by NanoEcho when we signed the most significant business agreement, so far, with SPL Medical. This ensures the accessibility of the nanoparticles that constitute the contrast agent of our diagnostic method, both for the planned clinical study and for our future sales.
